Literature DB >> 18254482

Atopic irritable bowel syndrome: a novel subgroup of irritable bowel syndrome with allergic manifestations.

Mary C Tobin1, Bhavani Moparty, Ashkan Farhadi, Mark T DeMeo, Priya J Bansal, Ali Keshavarzian.   

Abstract

BACKGROUND: Mast cells have a primary role in atopy. Mast cells may play a unique role in a subgroup of patients with irritable bowel syndrome (IBS). This observation suggests a link between atopic disorders and IBS.
OBJECTIVE: To determine whether there is an association between atopic disorders and IBS.
METHODS: We undertook a prospective study using structured questionnaires. We administered questionnaires to 125 consecutive patients seen in the following clinics from July 1 through October 31, 2001: allergy/immunology (AI) (n = 39), gastroenterology (n = 36), and general medicine (n = 50). The survey included questions detailing gastrointestinal and allergic symptoms. Diagnosis of IBS was based on Rome II criteria. Diagnosis of atopy was based on clinical parameters.
RESULTS: The AI clinic reported a significantly (P = .015) higher rate of IBS than the general medicine clinic. The IBS incidence reported in the AI clinic was similar to that reported in the gastroenterology clinic. The likelihood of IBS was significantly higher in patients with seasonal allergic rhinitis (2.67 times; 95% confidence interval [CI], 1.10-6.49; P = .03), patients with allergic eczema (3.85 times; 95% CI, 1.72-8.60; P = .001), and patients with depression (2.56 times; 95% CI, 1.05-6.14; P = .04). Patients reporting atopic symptoms (seasonal allergic rhinitis, allergic eczema, and asthma) were 3.20 times (95% CI, 1.20-8.50) (P = .02) more likely to fulfill the criteria for IBS.
CONCLUSIONS: Adults with atopic symptoms report a high incidence of IBS, suggesting a link between atopy and IBS. We proposed a subgroup of patients with IBS (atopic IBS) who have typical IBS symptoms in association with atopic manifestations. Identifying atopic vs nonatopic IBS may help in identifyingthe underlying pathophysiologic mechanisms and therapeutic options.

Entities:  

Mesh:

Year:  2008        PMID: 18254482     DOI: 10.1016/S1081-1206(10)60404-8

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  23 in total

1.  Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome.

Authors:  Olga Bednarska; Susanna A Walter; Maite Casado-Bedmar; Magnus Ström; Eloísa Salvo-Romero; Maria Vicario; Emeran A Mayer; Åsa V Keita
Journal:  Gastroenterology       Date:  2017-07-13       Impact factor: 22.682

2.  Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis.

Authors:  M Camilleri; P Carlson; S McKinzie; M Zucchelli; M D'Amato; I Busciglio; D Burton; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2011-07-14       Impact factor: 3.598

Review 3.  Food allergy in irritable bowel syndrome: The case of non-celiac wheat sensitivity.

Authors:  Pasquale Mansueto; Alberto D'Alcamo; Aurelio Seidita; Antonio Carroccio
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

4.  Excess risk of temporomandibular disorder associated with cigarette smoking in young adults.

Authors:  Anne E Sanders; William Maixner; Andrea G Nackley; Luda Diatchenko; Kunthel By; Vanessa E Miller; Gary D Slade
Journal:  J Pain       Date:  2011-10-26       Impact factor: 5.820

5.  Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.

Authors:  Gregory D Scott; Allison D Fryer
Journal:  Chem Immunol Allergy       Date:  2012-06-26

Review 6.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

Review 7.  Immunoglobulin E in irritable bowel syndrome: another target for treatment? A case report and literature review.

Authors:  James S Pearson; Robert M Niven; Jie Meng; Sima Atarodi; Peter J Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2015-09       Impact factor: 4.409

8.  Functional Gastrointestinal Symptoms Are Associated with Higher Serum Total IgE Levels, but Less Atopic Sensitization.

Authors:  Ellen Johanne Vara; Cecilie Svanes; Trude D Skorge; Aud Berstad; Erik Florvaag; Debbie Jarvis; Ernst Omenaas; Marie Waatevik; Ane Johannessen; Gülen Arslan Lied
Journal:  Dig Dis Sci       Date:  2015-08-12       Impact factor: 3.199

9.  Local immune response to food antigens drives meal-induced abdominal pain.

Authors:  Javier Aguilera-Lizarraga; Morgane V Florens; Maria Francesca Viola; Piyush Jain; Lisse Decraecker; Iris Appeltans; Maria Cuende-Estevez; Naomi Fabre; Kim Van Beek; Eluisa Perna; Dafne Balemans; Nathalie Stakenborg; Stavroula Theofanous; Goele Bosmans; Stéphanie U Mondelaers; Gianluca Matteoli; Sales Ibiza Martínez; Cintya Lopez-Lopez; Josue Jaramillo-Polanco; Karel Talavera; Yeranddy A Alpizar; Thorsten B Feyerabend; Hans-Reimer Rodewald; Ricard Farre; Frank A Redegeld; Jiyeon Si; Jeroen Raes; Christine Breynaert; Rik Schrijvers; Cédric Bosteels; Bart N Lambrecht; Scott D Boyd; Ramona A Hoh; Deirdre Cabooter; Maxim Nelis; Patrick Augustijns; Sven Hendrix; Jessica Strid; Raf Bisschops; David E Reed; Stephen J Vanner; Alexandre Denadai-Souza; Mira M Wouters; Guy E Boeckxstaens
Journal:  Nature       Date:  2021-01-13       Impact factor: 49.962

10.  Mast cell stabilizer ketotifen fumarate reverses inflammatory but not neuropathic-induced mechanical pain in mice.

Authors:  Carolina B Meloto; Pablo Ingelmo; Eduardo Vega Perez; Rebecca Pitt; Víctor Hugo González Cárdenas; Nada Mohamed; Susana G Sotocinal; Valerie Bourassa; Lucas Vasconcelos Lima; Alfredo Ribeiro-da-Silva; Jeffrey S Mogil; Luda Diatchenko
Journal:  Pain Rep       Date:  2021-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.